Dr Amos Akintayo Fatokun is currently a Senior Lecturer in Pharmacology within the School of Pharmacy and Biomolecular Sciences.
ACADEMIC AND PROFESSIONAL DEGREES:
Dr Fatokun trained as a pharmacist at the Obafemi Awolowo University, Nigeria, graduating in 2000 with a BPharm (with Distinction - the highest grade possible) and as the best student in the final Clinical Pharmacology course (module), before he studied between 2003 and 2006 for a PhD in Pharmacology and Neuroscience at the University of Glasgow in Scotland, UK, partly funded by the Federal Government of Nigeria’s Special Overseas Scholarship. He achieved a rare feat in his PhD viva in that no single correction was required to his thesis that was completed in record time (under 3 years) (thesis title: “Oxidative Stress and the Viability of Osteoblasts and Cerebellar Granule Neurones,” with Professors Trevor W. Stone and Robert A. Smith as supervisors). The thesis received a further accolade as runner-up (close second) of the British Neuroscience Association's (BNA) Prize for the best Neuroscience PhD in the UK in 2006.
He holds a Postgraduate Certificate in Higher Education Practice (PGCHEP) and is a Fellow of the UK Higher Education Academy (FHEA).
POSTDOCTORAL RESEARCH (MOSTLY FUNDED BY COMPETITIVE FELLOWSHIPS):
Dr Fatokun conducted postdoctoral research with the aid of competitive fellowships, each obtained at first attempt, at several prestigious institutions across the world:
2011 – 2013: EU FP7 Marie Curie International Incoming Fellowship (IIF) (FP7-PEOPLE-2010-IIF; Project Reference Number 274177), Institute of Cell Signalling, Queen’s Medical Centre, University of Nottingham, UK (with Professor Stephen J. Hill as host/mentor).
2010 – 2012: Nottingham Advanced Research Fellowship (NARF), Institute of Cell Signalling, Queen’s Medical Centre, University of Nottingham, UK (with Professor Stephen J. Hill as host/mentor).
2010 – 2010: Royal Society of Edinburgh (RSE) International Research Exchange Fellow, Drug Metabolism and Pharmacokinetics (DMPK) Group, Drug Discovery Unit, University of Dundee, UK (with Dr. Kevin D. Read as host).
2010-2010: International Visiting Research Fellowship (IVRF), University of Sydney, Australia (with Professor Nick H. Hunt as host).
2007 – 2010: American Heart Association (AHA) Postdoctoral Fellowship (best applicant in the round for the Mid-Atlantic Affiliate Region), Neuroregeneration and Stem Cells Programs, Institute for Cell Engineering, and the Department of Neurology, The Johns Hopkins University School of Medicine, USA (with Professors Ted M. Dawson and Valina L. Dawson as host/mentors).
2006 – 2007: University of Glasgow, UK (postdoc funded by Epsom Medical Research, UK, with Professor Trevor W. Stone, Dr Gail L. Darlington and Professor Robert A. Smith as mentors).
LECTURESHIPS (FACULTY POSITIONS):
In 2013 he secured a lectureship in Pharmacology at the School of Pharmacy, University of Bradford, UK, followed in 2014 by a lectureship in Medical Sciences within the School of Medical Sciences of the same institution. In October 2016 he was appointed a Senior Lecturer in Pharmacology at Liverpool John Moores University.
Dr Fatokun's research focusses on elucidating the cellular and molecular mechanisms underlying disease conditions characterised by either excessive cell death, e.g., neurodegenerative diseases (such as Parkinson's Disease and Alzheimer's Disease), or impaired cell death (such as cancers), with a view to harnessing the knowledge to develop novel therapeutics that will be more efficacious and elicit less side effects in managing those conditions. He uses state-of-the-art methodologies in pharmacology, physiology, biochemistry, cell and molecular biology, imaging, structural biology (through collaboration) and bioinformatics (through collaboration). He currently has collaborations with colleagues in the UK, Finland, South Africa and Nigeria.
His work is significantly translational (bench to bedside) and to some degree captures a wider context beyond cell death perturbations to assist in developing and optimising phenotypic- and target-based assays for high-throughput screening (HTS) of small molecules to identify those acting at a (druggable) molecular target of interest.
In summary, his current research interests include:
(1) Exploring cellular and molecular mechanisms of cell death in neurodegeneration.
(2) Oxidative stress (and nitrosative stress) and antioxidant signalling, including the Nrf2/ARE signalling pathway.
(3) Prospecting for novel anti-cancer drug leads.
(4) Development and optimisation of phenotypic and target-based assays for high-throughput screening (HTS) of chemical libraries (for various drug targets), HTS and compound characterisation/optimisation.
(5) Development of novel screening platforms and technologies, including the use of 3D cell culture models, stem cells and patient-derived cells.
(6) Natural products pharmacology and toxicology.
(7) Drug repurposing/repositioning.
(8) Use of fluorescent ligands to study novel pharmacology.
EXAMPLES OF CURRENT RESEARCH:
1. Investigating poly (ADP-ribose) polymerase (PARP)-dependent cell death, otherwise termed (and more recently known as) parthanatos, and developing novel, natural-compound or natural compound-inspired synthetic, PARP inhibitors or inhibitors acting at specific levels of the parthanatos pathway. PARP is a nuclear enzyme that senses DNA damage and thus helps to efficiently repair single-strand DNA nicks and breaks. It therefore contributes to the maintenance of cellular homoeostasis and the preservation of genomic stability under physiological conditions. However, its excessive activation, seen in pathological states, such as those of neurodegenerative diseases, can, and does, engender cell death, which explains its role in their pathophysiology. To date, PARP is known to exist in 17 different isoforms, although PARP-1 is the most widely-studied. Parthanatos as a cell death pathway is highly choreographed and distinct from apoptosis, necrosis and other forms of cell death, sequentially featuring overactivation of the enzyme PARP, the production of a prodigious amount of its polymer, poly (ADP-ribose) (PAR) and PAR-induced translocation to the nucleus of the mitochondrially-localised apoptosis-inducing factor (AIF), which when it enters the nucleus causes large-scale DNA fragmentation and chromatin condensation, culminating in parthanatic cell death.
Inhibitors of PARP can be developed and used, at least, as:
(i) Anti-cancer agents, especially for cancers that harbour mutations in the tumour-suppressor genes BRCA1 and BRCA2 (e.g., some breast, ovarian, cervical and prostate cancers). Current examples in the clinic include olaparib, rucaparib and niraparib (the drugs cause cancer cells to die through the process of synthetic lethality). PARP inhibitors can also be used in cancers without such mutations to sensitise the cancer cells to other anti-cancer agents, thus potentiating their cancer cell-killing effect (with the benefit that the dose of the other anti-cancer agent can be reduced), or to combat chemoresistance (preventing cancer cells from becoming resistant to anti-cancer agents that they have been previously sensitive to).
(ii) Neuroprotective agents: neurones can be rescued from death through blockade of parthanatos, preferably at some point(s) downstream of PARP activation, e.g., blockers of AIF translocation from the mitochondria to the nucleus.
We have identified some natural-compound inhibitors of PARP that ameliorate or prevent parthanatos and are neuroprotective. We are continuing to search for, and characterise, further novel inhibitors of parthanatos.
2. Natural compounds eliciting novel biological activities: Natural compounds maintain a pride of place in drug discovery, represent a unique inspiration for synthesis of novel bioactive molecules and demonstrate significant chemical diversity that affords an extensive exploration of the chemical space. Dr Fatokun explores medicinal plants for novel bioactivities, working with medicinal and synthetic chemists to advance the plants’ promising chemical constituents to drug leads, which, if sufficiently drug-like, could be further progressed in the drug development pipeline.
Compounds or their synthetic derivatives are tested for biological activities, potency, target selectivity, safety or tolerability profiles, physico-chemical parameters governing drug-likeness, etc.
3. Oxidative stress signalling: Dr Fatokun investigates oxidative stress and anti-oxidant signalling, especially in neurodegeneration, and the mechanisms of action of known or putative antioxidants, including their modulation of the Nrf2-ARE pathway.
PUBLICATIONS, AWARDS, PROFESSIONAL SERVICES
Dr Fatokun has published several papers in leading international journals (for further details, click the tab on 'Publications') and won several awards for the quality and impact of his work, including recognition as runner-up (close second) for the British Neuroscience Association's (BNA) Prize for the best Neuroscience PhD in the UK in 2006, the Pfizer Prize for best oral communication at the Pfizer Colloquium of the International Annual Meeting of the UK Biochemical Society, and the Alzheimer’s Drug Discovery Foundation (ADDF) Young Investigator Scholarship.
He is an Ambassador of the British Pharmacological Society (BPS) and a UK STEM Ambassador. He also engages in outreaches and activities in science communication.
He is a member of the British Pharmacological Society (BPS), The Physiological Society (PhySoc), the Biochemical Society and the Royal Society of Chemistry (MRSC).
He regularly reviews manuscripts for several international journals and research grant applications for a number of national and international funding agencies.
He organises and/or delivers academic workshops in several countries, for example, through the Newton Fund and the Researcher Connect Schemes of the British Council (UK) (workshops in Thailand, China, Brazil, Kazakhstan, etc.). He is passionate in leading research capacity building initiatives in the developing countries of the world, and in this regard has given several impactful lectures and seminars and/or led research or professional career development sessions in Africa, Asia and South America through visits to universities and other research establishments and also through delivering invited talks at conferences. He is a visiting academic to some of the institutions.
He has supervised/mentored undergraduate and postgraduate students and postdoctoral fellows (and continues to do so), some of whom have subsequently obtained prestigious research funding and/or published papers of significant impact.
Dr Fatokun is willing to consider enquiries on participating in/hosting/facilitating:
- Research collaborations
- PhD studies (studentships, scholarships, self-funded), either on a full-time, part-time or split-site basis
- Postdoctoral research, including through competitive fellowships
- Visiting research, summer placements, research experience placements, etc.
- Training in research methods and research-related soft skills development (including research grant writing, manuscript writing, science communication, etc.)
- Conference talks, institutional seminars, etc.
- Professional development sessions
- Research capacity development initiatives
- Industrial-academic partnerships
- STEM (Science, Technology, Engineering, Mathematics) Engagements
- Science communication outreaches and activities
- Any other relevant scholastic and professional engagements
CURRENT AND RECENT AREAS OF TEACHING:
Receptor pharmacology; Central Nervous System (CNS) pharmacology, including mechanisms of cell death in the CNS; Pharmacogenetics and personalised medicines; Adverse drug reactions (ADRs); Clinical trials; Liver and renal clearances; Respiratory physiology and cardiovascular physiology; Personal and professional development.
ResearcherID (Web of Science): T-7918-2017
Scopus Author ID: 14053823100
2016, University of Bradford, United Kingdom, PGCHEP (Postgraduate Certificate in Higher Education Practice)
2006, University of Glasgow, Glasgow, United Kingdom, PhD
2000, Obafemi Awolowo University, Nigeria, BPharm (Bachelor of Pharmacy) with Distinction
Senior Lecturer in Pharmacology, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, 2016 - present
Lecturer in Medical Sciences, School of Medical Sciences, Faculty of Life Sciences, University of Bradford, 2014 - 2016
Lecturer in Pharmacology, School of Pharmacy, Faculty of Life Sciences, University of Bradford, 2013 - 2014
Fatokun AA. 2018. Parthanatos: Poly (ADP-ribose) polymerase (PARP)-mediated cell death. In: ‘Apoptosis and Beyond: The Many Ways Cells Die'. Radosevich JA. Wiley Publishers. In Press
Zhang J, Marsh JR, Tait A, Iqbal MM, Pritchard CJ, MA A, Shang L, Fatokun AA. 2017. Methoxylated but not hydroxylated flavones elicit significant activity against PARP-1-mediated cell death (parthanatos). 38th World Congress (Rhythms of Life) of the International Union of Physiological Societies (IUPS), 1-5 August, 2017, Rio de Janeiro, Brazil.
Idowu SO, Adeyemo MA, Fatokun AA. 2014. Biomimetic attributes of novel lipophilicity assay affords reliable prediction of biopharmaceutical profile of small-molecule drugs. Biotechnology for Health and Sustainable Development, 4th Unibadan Conference of Biomedical Research, July 1-4, 2014, International Conference Centre, University of Ibadan, Ibadan, Nigeria.
Fatokun AA. 2014. Blending biophysical and drug discovery platforms to investigate allosterism in G-protein-coupled receptors (GPCRs) and find novel allosteric modulators for neurotherapeutics development. Marie Sklodowska Curie Actions (MSCA) Conference: The Empowerment of the Next Generation of Researchers: “Promoting talents, spreading excellence.” Book of Abstracts p. 10. November 18-19, Trento, Italy
Fatokun AA, Middleton RJ, Thompson KSJ, Briddon SJ, Hill SJ. 2013. Characterization of a novel, high-affinity and selective fluorescent antagonist for the 5HT1A receptor Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) >Link
Bakmiwewa SM, Fatokun AA, Liu Y, Tran A, Metz R, Prendergast GC, Payne RJ, Hunt NH, Ball HJ. 2012. Biochemical and biological properties of mouse indoleamine 2,3-dioxygenase-2 (IDO2) 13th International Society for Tryptophan Research Conference (ISTRY2012), Sydney, Australia
Fatokun AA, Dawson VL, Dawson TM. 2009. A high-throughput screen of small molecules reveals 4′-methoxyflavone as a neuroprotective PARP-1 inhibitor. American Society for Neuroscience (SfN) Annual Meeting (Neuroscience 2009), Chicago, USA
Smith RA, Fatokun AA, Smith AJ, Stone TW. 2009. Oxidative and nitrosative stress-induced neurotoxicity in primary cultured rat cerebellar granule neurons 46th Congress of the European-Societies-of-Toxicology >Link
Fatokun AA, Stone TW, Smith RA. 2007. Toppling a healthy balance: the menace of lovers of electrons. The Ninth Great British Research and R & D Show, House of Commons, Westminster, London, UK.
Fatokun AA, Stone TW, Smith RA. 2007. Potassium cyanide and 3-nitropropionic acid induce similar NMDA receptor-dependent neurotoxic pathways in vitro British Neuroscience Association (BNA) Meeting, Harrogate, UK
Fatokun AA, Stone TW, Smith RA. 2007. Induction by 3-nitropropionic acid and potassium cyanide of NMDA receptor-dependent generation of reactive oxygen species in cerebellar granule neurons: similarities and differences. FEBS Workshop “Generating neural diversity in the brain.” Hotel La Palma, Capri, Italy,
Fatokun AA, Stone TW, Smith RA. 2007. Prolonged but not short exposure to the nitric oxide donor S-nitroso-N-acetylpenicillamine (SNAP) may deplete superoxide and induce damage unrelated to peroxynitrite. The American Society for Neuroscience (SfN) Annual Meeting (Neuroscience 2007), San Diego, California, USA
Fatokun AA, Stone TW, Smith RA. 2006. Apoptotic and necrotic mechanisms of glutamate-induced neurotoxicity and protection by adenosine receptors The American Society for Neuroscience (SfN) Annual Meeting (Neuroscience 2006), Atlanta, GA, USA
Fatokun AA, Ukponmwan OE. 2005. Behavioural Modulation by Diazepam and Rapid Eye Movement Sleep Deprivation-induced Stress in the Rat Society for Neuroscientists of Africa (SONA)/International Brain Research Organization (IBRO) Conference, Cape Town, South Africa
Fatokun AA, Stone TW, Smith RA. 2005. Differentiation of osteoblast-like MC3T3-E1 cells increases sensitivity to oxidative stress damage Biochemical Society’s International Annual Meeting (Bioscience 2005), SECC, Glasgow, UK
Fatokun AA, Stone TW, Smith RA. 2005. Oxidative stress and glutamate toxicity in neurons and bone cells: parallels and contrasts The American Society for Neuroscience (SfN) Annual Meeting (Neuroscience 2005), Washington DC, USA
Fatokun AA, Stone TW, Smith RA. 2005. Aspects of glutamate signalling in bone: Hydrogen peroxide-induced oxidative stress in the osteoblast-like MC3T3-E1 cell line 13th Biennial Meeting of the Society-for-Free-Radical-Research >Link
Taiwo BJ, Fatokun AA, Olubiyi OO, Bamigboye-Taiwo OT, van Heerden FR, Wright CW. 2017. Identification of compounds with cytotoxic activity from the leaf of the Nigerian medicinal plant, Anacardium occidentale L. (Anacardiaceae) BIOORGANIC & MEDICINAL CHEMISTRY, 25 :2327-2335 >DOI >Link
Taiwo BJ, Taiwo GO, Olubiyi OO, Fatokun AA. 2016. Polyphenolic compounds with anti-tumour potential from Corchorus olitorius (L.) Tiliaceae, a Nigerian leaf vegetable BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 26 :3404-3410 >DOI >Link
Popoola TD, Awodele O, Omisanya A, Obi N, Umezinwa C, Fatokun AA. 2016. Three indigenous plants used in anti-cancer remedies, Garcinia kola Heckel (stem bark), Uvaria chamae P. Beauv. (root) and Olax subscorpioidea Oliv. (root) show analgesic and anti-inflammatory activities in animal models JOURNAL OF ETHNOPHARMACOLOGY, 194 :440-449 >DOI >Link
Fatokun AA, Tome M, Smith RA, Darlington LG, Stone TW. 2015. Protection by the flavonoids quercetin and luteolin against peroxide- or menadione-induced oxidative stress in MC3T3-E1 osteoblast cells NATURAL PRODUCT RESEARCH, 29 :1127-1132 >DOI >Link
Fatokun AA, Liu JO, Dawson VL, Dawson TM. 2013. Identification through high-throughput screening of 4 '-methoxyflavone and 3 ',4 '-dimethoxyflavone as novel neuroprotective inhibitors of parthanatos BRITISH JOURNAL OF PHARMACOLOGY, 169 :1263-1278 >DOI >Link
Bakmiwewa SM, Fatokun AA, Anh T, Payne RJ, Hunt NH, Ball HJ. 2012. Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 22 :7641-7646 >DOI >Link
Fatokun AA. 2011. Gaining notoriety through translocation: a case of the apoptosis-inducing factor (AIF) in poly (ADP-ribose) polymerase (PARP)-1-dependent neuronal death. Biokemistri, 23 :98-107
Fatokun AA, Stone TW, Smith RA. 2008. Prolonged exposures of cerebellar granule neurons to S-nitroso-N-acetylpenicillamine (SNAP) induce neuronal damage independently of peroxynitrite BRAIN RESEARCH, 1230 :265-272 >DOI >Link
Fatokun AA, Stone TW, Smith RA. 2008. Adenosine receptor ligands protect against a combination of apoptotic and necrotic cell death in cerebellar granule neurons EXPERIMENTAL BRAIN RESEARCH, 186 :151-160 >DOI >Link
Fatokun AA, Stone TW, Smith RA. 2008. Prolonged exposures of cerebellar granule neurons to S-nitroso-N- acetylpenicillamine (SNAP) induce neuronal damage independently of peroxynitrite Brain Research, 1230 :265-272 >DOI
Fatokun AA, Smith RA, Stone TW. 2008. Resistance to kynurenic acid of the NMDA receptor-dependent toxicity of 3-nitroproplonic acid and cyanide in cerebellar granule neurons BRAIN RESEARCH, 1215 :200-207 >DOI >Link
Fatokun AA. 2007. Glutamate signalling: From the CNS to the periphery- A new role for an old face? British Neuroscience Association Bulletin, 57 :14-16
Fatokun AA, Stone TW, Smith RA. 2007. Cell death in rat cerebellar granule neurons induced by hydrogen peroxide in vitro: Mechanisms and protection by adenosine receptor ligands BRAIN RESEARCH, 1132 :193-202 >DOI >Link
Fatokun AA. 2011. Review of “Sociology for Pharmacists: An Introduction” by Kevin Taylor, Sarah Nettleton and Geoffrey Harding. The Biochemist, 33 :58-58
Fatokun AA, Stone TW, Smith RA. 2005. Oxidative stress and glutamate signalling in osteoblast-like MC3T3-E1 cells Proceedings of the Meeting of the Society for Free Radical Research Europe, 13th Biennial Meeting of the Society-for-Free-Radical-Research :39-42 >Link
Engagement & Impact
The Use of Cell Culture in Cancer Research (Plenary Talk) (2017), Annual Faculty Seminar, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Lagos, Lagos State, Nigeria, Oral presentation
Advances in effective drug discovery, evaluation and development (Plenary Talk) (2015), 38th Conference of the West African Society for Pharmacology/Société Ouest Africaine de Pharmacologie (WASP-SOAP), Obafemi Awolowo University, Ile-Ife, Nigeria, Oral presentation
Molecular mechanisms of (neuronal) cell death: convergence or divergence of multiple pathways?, Latest Advances in Drug Discovery Informatics eCheminfo 2009 Interaction Meeting (Douglas Connect), Bryn Mawr College, Bryn Mawr, Philadelphia, USA, Oral presentation
Identification and characterisation of two novel, neuroprotective PARP-1 inhibitors, Pharmacology 2010, Queen Elizabeth II Conference Centre, London, UK, Oral presentation
Membership of professional bodies:
Member, Marie Curie Alumni Association (MCAA), https://www.mariecuriealumni.eu/
Member, Royal Society of Chemistry, http://www.rsc.org/
Member, The Biochemical Society (UK), http://www.biochemistry.org/
Member, The Physiological Society (UK), http://www.physoc.org/
Member and Ambassador, British Pharmacological Society (BPS), http://www.bps.ac.uk/
Other Professional Activity:
GRANT REVIEW (SELECTED): The Biotechnology and Biological Sciences Research Council (BBSRC); Newton International Fellowship; Institutional Links Grants, the British Council, UK; Researcher Links Workshops Grants, the British Council, UK; Kazakhstan's National Centre of Science and Technology Education (NCSTE); National Science Centre, Poland; Portuguese Foundation for Science and Technology, Pharmacology and Pharmaceutical Sciences sub-area.
MANUSCRIPT/BOOK REVIEW (SELECTED): Human Molecular Genetics; Neuropharmacology; Current Medicinal Chemistry; Food and Function; Molecular BioSystems (Royal Society of Chemistry); RSC Advances (Royal Society of Chemistry); Natural Product Research; PLoS One; Bentham Science Publishers (eBook); Journal of Cell and Animal Biology (JCAB); International Journal of Nutrition and Metabolism; The Biochemist (book review: Sociology for Pharmacists); Expert Review of Proteomics; Cell and Molecular Life Sciences (CMLS); Brain Research; Experimental Brain Research.
Research Grants Awarded:
American Heart Association (AHA) Postdoctoral Fellowship, Johns Hopkins University School of Meidicne, MD, USA, Screening for blockers of apoptosis-inducing factor (AIF) translocation, Grant value (£): US$80,000
Royal Society of Edinburgh International Exchange Programme (Fellowship), Pharmacokinetics of novel inhibitors of poly (ADP-ribose) polymerase-1, Dr Kevin Read, Grant value (£): 2,750
International Visiting Research Fellowship, University of Sydney, Australia, Identification of inhibitors of indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) through high-throughput screening of FDA-approved drugs library, Co-Applicant: Professor Nick Hunt, Grant value (£): AU$17,500
Nottingham Advanced Research Fellowship, University of Nottingham, UK, An investigation of allosteric modulation of selected GPCRs and their receptor interactions through single-cell fluorescence correlation spectroscopy and kinetic measurements, Grant value (£): 116,778, Duration of research project: 2 years
Biochemical Society's Guildford Bench Methodology Fund, Validating the biomimetic attributes of a novel lipophilicity assay, Co-applicant: Professor Olakunle Idowu, Grant value (£): 1,800
EU FP7 Marie Curie International Incoming Fellowship (IIF), European Commission, Blending biophysical and drug discovery platforms to investigate allosterism in G-protein-coupled receptors (GPCRs) and find novel allosteric modulators for neurotherapeutics development, Grant value (£): €210,000, Duration of research project: 2 years
University of Oulu (Finland) Visiting Research Grant, Using biochemical assays and protein X-ray crystallography to investigate mechanisms of interactions between flavones and poly (ADP-ribose) polymerases (PARPs), Co-applicant: Dr Lari Lehtio, Grant value (£): €1,700
The Biochemical Society (Eric Reid Methodology Fund), Natural product modulation of poly (ADP-ribose) polymerase (PARP) signalling in cell death, Grant value (£): 2,000
Royal Society of Chemistry (RSC) (Research Funds), Characterisation and optimisation of natural compound inhibitors of poly (ADP-ribose) polymerase (PARP), Grant value (£): 4,000, Duration of research project: 2 years
Liverpool John Moores University, Collaboration on Bioinformatics with Dr Andreas Bender, Department of Chemistry and Centre for Molecular Informatics, University of Cambridge, UK, Grant value (£): 6,000
Newton Fund/Liverpool John Moores University, Collaboration visit to the School of Chemistry, University of KwaZulu-Natal, South Africa (host: Prof. Fanie van Heerden), Grant value (£): 2,250
Liverpool John Moores University, Faculty of Science, Seed Corn Research Grant, Grant value (£): 10,000
Fellow of the UK Higher Education Academy (FHEA)
Postgraduate Certificate in Higher Education Practice (PGCHEP)